Gilead Sciences, Inc. announced that it has completed its acquisition of CV Therapeutics, Inc.
On April 17, 2009, CV Therapeutics merged with a wholly-owned subsidiary of Gilead. As a result of the merger, each outstanding share of CV Therapeutics not owned by Gilead, its subsidiaries or CV Therapeutics has been automatically converted into the right to receive $20.00 in cash, without interest, subject to appraisal rights. CV Therapeutics stockholders who did not tender their shares will receive a Notice of Merger and a Letter of Transmittal that will instruct them as to how to receive the merger consideration. The merger follows a cash tender offer for all outstanding shares of CV Therapeutics common stock at $20.00 per share, which was completed at one minute following 11:59 p.m., New York City time (midnight), on April 14, 2009.
Release Date: April 17, 2009
Source: Gilead Sciences
